Previous 10 | Next 10 |
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the close of market on Wednesday, July 27, 2022. The release will be accessible on Taro’s website at www.taro.com...
Based on the current long-term trend, shares look like they will test long-term support. We expect support to hold there based on the company's strong earnings power and clean balance sheet. Adjusted cash flow numbers also remain strong. Investors may need to buy the fear here whe...
Taro Pharmaceutical press release (NYSE:TARO): Q4 GAAP EPS of $0.73. Revenue of $143.26M (-3.4% Y/Y). For further details see: Taro Pharmaceutical GAAP EPS of $0.73, revenue of $143.26M
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021 The qu...
Taro Pharmaceutical (NYSE:TARO) is scheduled to announce Q1 earnings results on Thursday, May 26th, after market close. The consensus EPS Estimate is $0.88 (+8.6% Y/Y) and the consensus Revenue Estimate is $147.01M (-0.9% Y/Y). Over the last 1 year, TARO has beaten EPS estimates 25% of the ti...
ADSK, AEO, COST, DELL, DOMO, FTCH, GPS, LGF.A, LIZI, MAXN, ME, MRVL, RRGB, SUMO, SVM, TARO, ULTA, VMW, WDAY, ZS For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's close
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2022, after the close of market on Thursday, May 26, 2022. The release will be accessible on Taro’s website at www.taro.com . ...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) today announced the completion of its acquisition of Alchemee, formerly The Proactiv Company (TPC), from Galderma. The acquisition includes Alchemee’s business and assets worldwide, including the Proactiv ...
Taro Pharmaceutical Industries (NYSE:TARO) will acquire Alchemee, formerly The Proactiv Company, from Galderma. The deal includes Alchemee’s business and assets around the world, including its flagship acne care brand Proactiv. Financial terms of the transaction have not been disclosed...
Alchemee’s flagship brand Proactiv® is an iconic product synonymous with acne care Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire Alchemee, f...
News, Short Squeeze, Breakout and More Instantly...
Taro Pharmaceutical Industries Ltd. Company Name:
TARO Stock Symbol:
NYSE Market:
Taro Pharmaceutical Industries Ltd. Website:
2024-06-03 08:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 09:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Taro Shareholders Approve Merger with Sun Pharma Canada NewsWire MUMBAI, India and NEW YORK , May 23, 2024 /CNW/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiar...